Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 3/20 | 0.33 |
| ▸ | RARB | P10826 | 2/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8945376 | 0.99 | FPR2 (0.33) | FPR2RARBRARAS1PR1SCN9A | |
| SCHEMBL8945751 | 0.98 | FPR2 (0.35) | FPR2RARBRARAPTPN11EPHX1 | |
| SCHEMBL8945223 | 0.98 | FPR2 (0.35) | FPR2RARBRARAPTPN11EPHX1 | |
| SCHEMBL8945433 | 0.98 | FPR2 (0.35) | FPR2RARBRARAPTPN11EPHX1 | |
| SCHEMBL8945797 | 0.98 | FPR2 (0.35) | FPR2RARBRARAPTPN11EPHX1 | |
| SCHEMBL8945390 | 0.98 | FPR2 (0.35) | FPR2RARBRARAPTPN11EPHX1 | |
| SCHEMBL8945439 | 0.98 | FPR2 (0.35) | FPR2RARBRARAPTPN11EPHX1 | |
| SCHEMBL8945229 | 0.98 | FPR2 (0.35) | FPR2RARBRARAPTPN11EPHX1 | |
| SCHEMBL8945748 | 0.98 | FPR2 (0.35) | FPR2RARBRARAPTPN11EPHX1 | |
| SCHEMBL8945746 | 0.98 | FPR2 (0.35) | FPR2RARBRARAPTPN11EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |